Viatris Inc. (NASDAQ:VTRS) is included among the 13 Best March Dividend Stocks to Buy.
On February 27, UBS raised its price recommendation on Viatris Inc. (NASDAQ:VTRS) to $20 from $18. It maintained a Buy rating on the stock. The firm noted that Viatris met its Q4 cost-saving goals and issued FY26 guidance that came in above consensus expectations. Still, the shares dropped 5%, following strong gains earlier in the year. The analyst told investors that the upcoming March 19 investor event could be important. It may lay out a path toward mid-single-digit revenue growth. UBS also said ongoing cost reductions could support a teen-level EPS compound annual growth rate, which may help drive meaningful multiple expansion over time.
The company also reported its Q4 2025 results. CEO Scott Smith said 2025 had been a strong year for Viatris. He stated that the company delivered solid financial performance and had positioned itself to enter a phase of sustainable long-term growth beginning in 2026. Smith reported total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion, pointing to the overall strength of the business.
He also highlighted progress in the company’s pipeline. Five Phase III studies delivered positive results, which he described as an important milestone. He added that enrollment in key programs, including cenerimod and selatogrel, was moving forward and expected to be completed in 2026. Smith said Viatris returned more than $1 billion to shareholders during the year through dividends and share repurchases. He also pointed to the completion of 60 regional transactions. These included the acquisition of Aculys Pharma in Japan, which he described as part of the company’s broader strategic plan.
Smith said the company expects to generate about $650 million in gross cost savings over three years. He added that up to $250 million of those savings will be reinvested into growth initiatives. He also said the company had prepared for a potential FDA reinspection of its Indore facility. Steps were taken to build operational redundancies, with the goal of maintaining continuity and stability.
Viatris Inc. (NASDAQ:VTRS) operates as a global healthcare company. Its business spans Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment includes its primary operations in North America and Europe.
While we acknowledge the potential of VTRS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VTRS and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 14 Value Stocks to Buy With High Dividend Yields and 13 Best Long-Term Dividend Stocks to Invest in Right Now
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center